Aileron Therapeutics Inc. (ALRN)’s Financial Results Comparing With AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB)

Aileron Therapeutics Inc. (NASDAQ:ALRN) and AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aileron Therapeutics Inc. N/A 0.00 31.38M -2.13 0.00
AmpliPhi Biosciences Corporation N/A 405.29 10.14M -0.76 0.00

In table 1 we can see Aileron Therapeutics Inc. and AmpliPhi Biosciences Corporation’s gross revenue, earnings per share (EPS) and valuation.


Table 2 hightlights the return on assets, return on equity and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Aileron Therapeutics Inc. 0.00% -85% -70%
AmpliPhi Biosciences Corporation 0.00% -118.6% -84.7%


Aileron Therapeutics Inc. has a Current Ratio of 2.5 and a Quick Ratio of 2.5. Competitively, AmpliPhi Biosciences Corporation’s Current Ratio is 2.1 and has 2.1 Quick Ratio. Aileron Therapeutics Inc.’s better ability to pay short and long-term obligations than AmpliPhi Biosciences Corporation.

Institutional and Insider Ownership

Institutional investors owned 20.6% of Aileron Therapeutics Inc. shares and 5.7% of AmpliPhi Biosciences Corporation shares. Insiders owned roughly 16.4% of Aileron Therapeutics Inc.’s shares. Insiders Comparatively, owned 1.28% of AmpliPhi Biosciences Corporation shares.


Here are the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aileron Therapeutics Inc. -7.83% -2.44% -34.85% -62.83% -80.2% -81.02%
AmpliPhi Biosciences Corporation -21.59% -27.25% -78.61% -82.93% -79.24% -79.04%

For the past year Aileron Therapeutics Inc.’s stock price has bigger decline than AmpliPhi Biosciences Corporation.


AmpliPhi Biosciences Corporation beats on 4 of the 7 factors Aileron Therapeutics Inc.

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing a novel class of therapeutics in the United States. The companyÂ’s lead product includes ALRN-6924, a stapled peptide that in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial for the treatment of peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase II b trial for the treatment of AML/MDS in combination with cytosine arabinoside. It is also developing next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. It is also developing targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. The company has reported results from two Phase I clinical trials of AB-SA01 for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients, as well as evaluating the safety of AB-SA01 when administered topically to the intact skin of healthy adults. Its pipeline also includes AB-PA01 for the treatment of pseudomonas aeruginosa lung infections in cystic fibrosis and chronic rhinosinusitis patients. AmpliPhi Biosciences Corporation has a research collaboration agreement with Royal Brompton Hospital; a license agreement with University of Leicester to develop a phage therapy that targets and kills various clinically relevant toxin types of C. difficile; a cooperative research and development agreement with the U.S. Army Medical Research and Materiel Command and the Walter Reed Army Institute of Research to develop and commercialize bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and a clinical trial agreement with the University of Adelaide. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.